Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.06
Change (%) Stock is Up 0.57 (5.43%)
Volume284,989
Data as of 06/18/19 3:07 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
06/17/19Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
06/10/19Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs
06/05/19Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development
05/30/19Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
Upcoming EventsMore >>
DateTitle
07/22/19
through
07/24/19
Eiger BioPharmaceuticals at the10th Orphan Drug & Rare Disease 2019
LocationWest, SF
08/13/19
through
08/14/19
Eiger BioPharmaceuticals at Wedbush Pacgrow Healthcare Conference 2019
LocationNYC
09/05/19
Eiger BioPharmaceuticals at Citi 14th Annual Biotech Conference
LocationBoston
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.